[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma

Oncogene volume 41, pages 3570–3583 (2022)Cite this article

Subjects

Abstract

Liver cancer, a result of multifactorial interplay between heredity and the environment, is one of the leading causes of cancer-related death worldwide. Hepatocellular carcinoma (HCC) is the most common histologic type of primary liver cancer. Here, we reported that deficiency in PCDHB14, a member of the cadherin superfamily, participates in the progression of HCC. We found that PCDHB14 is inactivated by aberrant methylation of its promoter in HCC patients and that PCDHB14 functions as a tumor suppressor to promote cell cycle arrest, inhibit cell proliferation, and induce ferroptosis. Furthermore, PCDHB14 ablation dramatically enhanced diethylenenitrite-induced HCC development. Mechanistically, PCDHB14 is induced by p53, and increased PCDHB14 downregulates the expression of SLC7A11, which is critical for ferroptosis. This effect is mediated by accelerated p65 protein degradation resulting from PCDHB14 promoting E3 ubiquitin ligase RNF182-mediated ubiquitination of p65 to block p65 binding to the promoter of SLC7A11. This study reports the new discovery that PCDHB14 serves as a potential prognostic marker for HCC.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution
Fig. 1: PCDHB14 expression is decreased in tumor tissues and associated with prognosis in HCC patients.
Fig. 2: TP53 induces PCDHB14 expression.
Fig. 3: PCDHB14 inhibits malignant progression of liver cancer.
Fig. 4: PCDHB14 downregulation promotes malignant progression of liver cancer.
Fig. 5: PCDHB14 inhibits SLC7A11 expression to promote ferroptosis.
Fig. 6: PCDHB14 enhances RNF182-mediated ubiquitination of p65 by protein-to-protein binding.
Fig. 7: PCDHB14 deletion increases DEN-induced tumorigenesis in mice.

Similar content being viewed by others

References

  1. Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020;21:947–56.

    Article  CAS  Google Scholar 

  2. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–91.

    Article  Google Scholar 

  3. Li S, Liu R, Pan Q, Wang G, Cheng D, Yang J, et al. De novo lipogenesis is elicited dramatically in human hepatocellular carcinoma especially in hepatitis C virus-induced hepatocellular carcinoma. MedComm. 2020;1:178–87.

    Article  Google Scholar 

  4. Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68:526–49.

    Article  Google Scholar 

  5. Zhou X, Updegraff BL, Guo Y, Peyton M, Girard L, Larsen JE, et al. PROTOCADHERIN 7 acts through SET and PP2A to potentiate MAPK signaling by EGFR and KRAS during lung tumorigenesis. Cancer Res. 2017;77:187–97.

    Article  CAS  Google Scholar 

  6. Cao L, Riascos-Bernal D, Chinnasamy P, Dunaway C, Hou R, Pujato M, et al. Control of mitochondrial function and cell growth by the atypical cadherin Fat1. Nature. 2016;539:575–8.

    Article  CAS  Google Scholar 

  7. Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B, et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature. 2021;589:448–55.

    Article  CAS  Google Scholar 

  8. Morris L, Kaufman A, Gong Y, Ramaswami D, Walsh L, Turcan Ş, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet. 2013;45:253–61.

    Article  CAS  Google Scholar 

  9. Zhao Y, Yang Y, Trovik J, Sun K, Zhou L, Jiang P, et al. A novel wnt regulatory axis in endometrioid endometrial cancer. Cancer Res. 2014;74:5103–17.

    Article  CAS  Google Scholar 

  10. Yu J, Koujak S, Nagase S, Li C, Su T, Wang X, et al. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene. 2008;27:4657–65.

    Article  CAS  Google Scholar 

  11. Liang C, Zhang X, Yang M, Dong X. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 2019;31:e1904197.

    Article  Google Scholar 

  12. Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, et al. Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ. 2019;26:2329–43.

    Article  CAS  Google Scholar 

  13. Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20:1181–92.

    Article  CAS  Google Scholar 

  14. Bersuker K, Hendricks J, Li Z, Magtanong L, Ford B, Tang P, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688–92.

    Article  CAS  Google Scholar 

  15. Chen L, Liu S, Tao Y. Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther. 2020;5:90.

    Article  CAS  Google Scholar 

  16. Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57–62.

    Article  CAS  Google Scholar 

  17. Liu Y, Mao C, Wang M, Liu N, Ouyang L, Liu S, et al. Cancer progression is mediated by proline catabolism in non-small cell lung cancer. Oncogene. 2020;39:2358–76.

    Article  CAS  Google Scholar 

  18. Chen L, Shi Y, Liu N, Wang Z, Yang R, Yan B, et al. DNA methylation modifier LSH inhibits p53 ubiquitination and transactivates p53 to promote lipid metabolism. Epigenetics Chromatin. 2019;12:59.

    Article  Google Scholar 

  19. Chen X, Li Y, Rubio K, Deng B, Li Y, Tang Q, et al. Lymphoid-specific helicase in epigenetics, DNA repair and cancer. Br J Cancer. 2022;126:165–73.

    Article  CAS  Google Scholar 

  20. Jiang Y, Mao C, Yang R, Yan B, Shi Y, Liu X, et al. EGLN1/c-Myc induced lymphoid-specific helicase inhibits ferroptosis through lipid metabolic gene expression changes. Theranostics. 2017;7:3293–305.

    Article  CAS  Google Scholar 

  21. Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med. 2021;13:e14351.

    Article  CAS  Google Scholar 

  22. Ye W, Ling S, Liu R, Pan Z, Wang G, Gao S, et al. Exome sequencing reveals the genetic landscape and frequent inactivation of PCDHB3 in Chinese rectal cancers. J Pathol. 2018;245:222–34.

    Article  CAS  Google Scholar 

  23. Cao Y, Sun Y, Chang H, Sun X, Yang S. The E3 ubiquitin ligase RNF182 inhibits TLR-triggered cytokine production through promoting p65 ubiquitination and degradation. FEBS Lett. 2019;593:3210–9.

    Article  CAS  Google Scholar 

  24. Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. MedComm. 2021;2:618–53.

    Article  CAS  Google Scholar 

  25. Zhang Y, Huo F, Wei L, Gong C, Pan Y, Mou J, et al. PAK5-mediated phosphorylation and nuclear translocation of NF-κB-p65 promotes breast cancer cell proliferation in vitro and in vivo. J Exp Clin Cancer Res. 2017;36:146.

    Article  Google Scholar 

  26. Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, et al. Epigenetic alteration: new insights moving from tissue to plasma – the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer. 2013;109:807–13.

    Article  CAS  Google Scholar 

  27. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 2009;136:640–1.

    Article  CAS  Google Scholar 

  28. Mao C, Wang X, Liu Y, Wang M, Yan B, Jiang Y, et al. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. Cancer Res. 2018;78:3484–96.

    Article  CAS  Google Scholar 

  29. Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63:173–84.

    Article  CAS  Google Scholar 

  30. Wang Z, Chen X, Liu N, Shi Y, Liu Y, Ouyang L, et al. A nuclear long non-coding RNA LINC00618 accelerates ferroptosis in a manner dependent upon apoptosis. Mol Ther. 2021;29:263–74.

    Article  CAS  Google Scholar 

  31. Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599–620.

    Article  CAS  Google Scholar 

  32. Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell. 2018;173:1413–4.

    Article  CAS  Google Scholar 

  33. Liu QY, Lei JX, Sikorska M, Liu R. A novel brain-enriched E3 ubiquitin ligase RNF182 is up regulated in the brains of Alzheimer’s patients and targets ATP6V0C for degradation. Mol Neurodegener. 2008;3:4.

    Article  Google Scholar 

  34. Voisinne G, Kersse K, Chaoui K, Lu L, Chaix J, Zhang L, et al. Quantitative interactomics in primary T cells unveils TCR signal diversification extent and dynamics. Nat Immunol. 2019;20:1530–41.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Prof. Yinming Liang for sharing mice. We also thank the contributions of all of Yongguang Tao’s lab members.

Funding

This work is supported by National Natural Science Foundation of China [81872285 (YS), 81874139 and 82073097 (SL), 82072594 (YT), 82073136 (DX)], Natural Science Foundation of Hunan Province [2021JJ30907 (YS)], [2020JJ5790 (CM)], [2021JJ40937 (YLiu)], China Postdoctoral Science Foundation [2021M700173 (YLiu)] and the Hunan Provincial Key Area R&D Program [2021SK2013 (YT)].

Author information

Authors and Affiliations

  1. Postdoctoral Research Station of Clinical Medicine & Department of Hematology and Critical Care Medicine, the 3rd Xiangya Hospital, Central South University, Changsha, 410000, P. R. China

    Yating Liu

  2. Department of Pathology, Xiangya Hospital, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Changsha, Hunan, 410078, P. R. China

    Yating Liu, Lianlian Ouyang, Chao Mao, Yuanbing Chen, Tiansheng Li, Na Liu, Zuli Wang, Weiwei Lai, Yanling Zhou, Ya Cao, Min Wang, Shouping Liu, Ling Chen, Ying Shi, Desheng Xiao & Yongguang Tao

  3. NHC Key Laboratory of Carcinogenesis (Central South University), Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, Hunan, 410078, P. R. China

    Yating Liu, Lianlian Ouyang, Chao Mao, Yuanbing Chen, Tiansheng Li, Na Liu, Zuli Wang, Weiwei Lai, Yanling Zhou, Min Wang, Shouping Liu, Ling Chen, Ying Shi, Desheng Xiao & Yongguang Tao

  4. Department of Oncology, Institute of Medical Sciences, National Clinical Research, Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China

    Shuang Liu

  5. School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, 453003, P. R. China

    Yinming Liang

  6. Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, Second Xiangya Hospital, Central South University, Changsha, 410011, P. R. China

    Yongguang Tao

Authors
  1. Yating Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lianlian Ouyang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chao Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuanbing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tiansheng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Na Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zuli Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Weiwei Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yanling Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ya Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shuang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yinming Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Min Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shouping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ling Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Ying Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Desheng Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Yongguang Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YT, YS, DX, and SL designed/planned the study and wrote the paper. YLiu performed experiments using the three types of cells and analyzed data. YLiu, CM, and NL participated in writing the paper. OY and DX performed imaging analysis. YLiu, YZ, YC, OY, and YLiang performed in vitro biochemical experiments. TL, ZW, DX, LC, YC, and YT participated in the discussion of related experiments. WL, SL, and NL performed computational modeling. XD acquired and analyzed clinical and experimental data. YLiu and OY performed experiments and analyzed data.

Corresponding authors

Correspondence to Ying Shi, Desheng Xiao or Yongguang Tao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Ouyang, L., Mao, C. et al. PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma. Oncogene 41, 3570–3583 (2022). https://doi.org/10.1038/s41388-022-02370-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-022-02370-2

This article is cited by

Search

Advanced search

Quick links